CPSF3 inhibitors are a class of chemical compounds specifically designed to target and inhibit the activity of Cleavage and Polyadenylation Specificity Factor 3 (CPSF3), an essential component of the pre-mRNA processing machinery. CPSF3 plays a pivotal role in the cleavage of pre-mRNA, a crucial step in the formation of mature messenger RNA (mRNA). The inhibitors of CPSF3 are characterized by their ability to bind to and obstruct the active site of CPSF3, thereby hindering its function in the mRNA processing pathway. This interaction is critical as it directly affects the efficacy of mRNA maturation and subsequent protein synthesis. The molecular structure of CPSF3 inhibitors is often complex, incorporating specific functional groups that are strategically positioned to maximize binding affinity and specificity. These structures usually include various moieties that are designed to interact with key domains of CPSF3, such as the catalytic center or the substrate binding regions.
The development and study of CPSF3 inhibitors involve a combination of advanced techniques in chemical synthesis, structural biology, and computational modeling. Researchers utilize high-throughput screening methods to identify inhibitory molecules, followed by iterative chemical modifications to enhance their selectivity and potency against CPSF3. Structural analysis methods such as X-ray crystallography or NMR spectroscopy are employed to elucidate the molecular interactions between these inhibitors and CPSF3. This detailed understanding is crucial for refining the inhibitors' design, ensuring that they effectively target CPSF3's active site. Additionally, the physicochemical properties of CPSF3 inhibitors, such as solubility, stability, and molecular weight, are vital considerations in their development. These properties are meticulously optimized to ensure that the inhibitors effectively interact with CPSF3, thereby influencing the mRNA processing pathway. The intricate design and development of CPSF3 inhibitors demonstrate the importance of understanding and modulating molecular mechanisms at the cellular level.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $90.00 $204.00 | 13 | |
Triptolide has been noted for its ability to inhibit general transcription, potentially affecting CPSF3 expression. | ||||||
α-Amanitin | 23109-05-9 | sc-202440 sc-202440A | 1 mg 5 mg | $269.00 $1050.00 | 26 | |
α-Amanitin inhibits RNA polymerase II, which could reduce overall mRNA synthesis including that of CPSF3. | ||||||
DRB | 53-85-0 | sc-200581 sc-200581A sc-200581B sc-200581C | 10 mg 50 mg 100 mg 250 mg | $43.00 $189.00 $316.00 $663.00 | 6 | |
DRB inhibits RNA Pol II phosphorylation and may lower CPSF3 mRNA production. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $259.00 | 41 | |
Flavopiridol inhibits CDK9, a part of the P-TEFb complex, impacting transcription elongation and potentially CPSF3 expression. | ||||||
Cordycepin | 73-03-0 | sc-203902 | 10 mg | $101.00 | 5 | |
Cordycepin disrupts mRNA synthesis and processing, which might result in reduced expression of CPSF3. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $231.00 $863.00 | 1 | |
JQ1 inhibits BET bromodomains, affecting the expression of certain genes, which may include CPSF3. | ||||||
GSK 525762A | 1260907-17-2 | sc-490339 sc-490339A sc-490339B sc-490339C sc-490339D | 5 mg 10 mg 50 mg 100 mg 1 g | $300.00 $540.00 $940.00 $1680.00 $5900.00 | ||
I-BET762 is another BET bromodomain inhibitor that could lead to downregulation of CPSF3 expression. | ||||||
Rocaglamide | 84573-16-0 | sc-203241 sc-203241A sc-203241B sc-203241C sc-203241D | 100 µg 1 mg 5 mg 10 mg 25 mg | $275.00 $474.00 $1639.00 $2497.00 $5344.00 | 4 | |
Rocaglamide inhibits translation initiation and could reduce protein levels of CPSF3. | ||||||
Homoharringtonine | 26833-87-4 | sc-202652 sc-202652A sc-202652B | 1 mg 5 mg 10 mg | $52.00 $125.00 $182.00 | 11 | |
Homoharringtonine inhibits protein translation initiation, potentially decreasing CPSF3 protein levels. | ||||||
Silvestrol | 697235-38-4 | sc-507504 | 1 mg | $920.00 | ||
Silvestrol, a translation inhibitor, may affect CPSF3 by reducing its translation. | ||||||